Briefing
Circulating Tumor DNA in Oligoprogressive Prostate Cancer Treated With Stereotactic Radiotherapy: A Prespecified Secondary Analysis of a Nonrandomized Clinical Trial (TRAP)
JAMA Network Open published online on November 11, 2026 a prespecified secondary analysis of the nonrandomized phase 2 TRAP trial: plasma was tested with the previously validated prostate-directed PCF_SELECT panel before stereotactic body radiotherapy in men with metastatic castration-resistant prostate cancer and oligoprogression on abiraterone or enzalutamide. Of 77 evaluable patients (81 treated at 8 UK sites), 19 (24.7%) were ctDNA-positive. Six-month progression-free survival was 21.1% versus 58.3%, and median progression-free survival was 3.0 versus 7.8 months (log-rank P = .003; adjusted HR 2.18, 95% CI 1.21-3.94, P = .009). Median time to next therapy or death was 15.3 versus 29.6 months (adjusted HR 1.57, P = .20), and median overall survival was 27.2 versus 33.6 months (adjusted HR 2.24, P = .07). The trial was not randomized, so a prognostic association is not separated from a predictive one.